PeptideStack
5.2kquestions
20kanswers
220users

If a liraglutide dose is missed by ten days, does the ladder reset?

Asked 19 Aug 2025Modified 8 months agoViewed 14k times
24

For reference: liraglutide · ten days.

I have read the obvious sources and they disagree with each other, so I would rather ask people who have actually done this.

I have a working setup and a notebook, and I am prepared to be told that my setup is inadequate if that is the answer.

Concretely, what should I do, and how would I know afterwards whether I did it right?

missed-dose
missed-dose

What the label instructions for a missed weekly dose are, why they differ between agents, and what the pharmacokinetics say about drift in an…

41 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
liraglutide
liraglutide

A once-daily GLP-1 receptor agonist and the compound that established the class. Still relevant for its shorter half-life, its paediatric and…

235 questions
shareeditfollowflag
MS
askedmarta_szymanska10k1519 Aug 2025

5 Answers

Sorted by votes
32

10 days past a due dose is 1.43 half-lives at the seven-day half-life this class runs on, which leaves about 37.1 per cent of that dose still circulating. One line of arithmetic: remaining fraction is one half raised to days over half-life, so 0.5^(10÷7) = 0.3715. At 37.1 per cent you have not been off it in any meaningful sense. The interval stretched from 7 days to 17 and the trough went lower than usual; that is the whole of what happened. What the product label says and what the pharmacokinetics say are two different answers here, and the first is the one that governs. Restarting, holding or stepping down after a gap is decided under supervision, and nothing here is medical advice.

Answer first: it depends on the half-life and on how long ago the dose was due, and for a weekly agent the tolerance is much wider than people fear.

For a daily agent with a thirteen-hour half-life, a missed dose is a much larger proportional loss. The usual approach is to skip it and take the next scheduled one rather than doubling.

Weekly dosing accumulation, 7-day half-life

WeekFraction of steady stateTrough as × dose
150 %0.50
275 %0.75
388 %0.88
494 %0.94
597 %0.97
698 %0.98

This is why a four-week step interval is approximately, but not exactly, steady state.

To change your regular dosing day, move the next dose later rather than earlier, keeping at least three days between doses for a weekly agent. Moving earlier compresses the interval and raises exposure.

Set a recurring reminder attached to something you already do weekly.

shareimprove this answerflag
LS
answeredlow_dead_space37k3720 Aug 2025
5The four-half-lives rule is the part everyone skips and it explains most of the misery. – Dr_Yusuf_Adeyemi 8 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
22

Answering this needs the agent, since the answer for a thirteen-hour half-life and a one-week half-life are entirely different.

With a one-week half-life dosed weekly, missing one dose means exposure falls by about half over the following week — the same trough you would reach if you simply extended the interval. That is well within the range the agent operates in.

Put another way, if more than two consecutive weekly doses are missed, tolerance to the gastrointestinal effects begins to fade and re-titration from a lower step becomes the sensible approach.

Two or more missed weekly doses means considering a lower restarting step.

shareimprove this answerflag
CD
answeredcolm_dunphy8.2k147 Dec 2025
15

The relevant arithmetic is that one missed dose of a weekly agent produces a trough about half the usual, which is well inside the normal range.

Set a recurring reminder tied to something you already do weekly. The commonest cause of a missed dose is not forgetting the drug but losing track of the day.

In practice, the published guidance for the weekly agents is broadly: if the missed dose is remembered within about five days, take it and continue on the usual day; if more than five days have passed, skip it and take the next scheduled dose.

Loss of tolerance during a treatment gap is documented and is the basis for re-titration after an interruption.

Within about five days for a weekly agent, take it. Beyond that, skip and resume.

shareimprove this answerflag
ID
answeredines_delacruz16k1626 Nov 2025
13

Start with the interval since the missed dose, because that single number determines the answer.

One missed dose is not a reason to change the schedule or the dose. Two or more is a reason to consider where you are restarting from.

The caveat is that anyone on other glucose-lowering medication has an interaction question here that needs a prescriber.

Never double up. Peak exposure is what drives the symptoms.

shareimprove this answerflag
EV
answeredekaterina_volk21k284 Nov 2025
8Adding for future readers: write down what "working" means before you start. – rota_site 9 months ago
add a comment
13

Changing the regular dosing day is possible and should be done by moving forward, not by squeezing two doses together.

Never take two doses close together to compensate. The peak exposure is roughly doubled, and gastrointestinal tolerability tracks peak exposure closely.

Half-lives across the class span roughly thirteen hours to one week, which is why the answer is agent-specific.

To move your dosing day, move it later and keep three days between doses.

shareimprove this answerflag
EL
answeredesben_lykke84k15815 Nov 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.